Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Sheldon Magder, MD
- Phone Number: 35253 514-934-1934
- Email: sheldon.magder@muhc.mcgill.ca
Study Contact Backup
- Name: Thomas Lescot, MD, PhD
- Phone Number: 36736 514-934-1934
- Email: thomas.lescot@mail.mcgill.ca
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A1A1
- Royal Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Patients from the Critical care Unit
- Patients with a pulmonary artery occlusion catheter Inclusion:patients immediately following liver transplantation
Exclusion Criteria:
- Patients not giving informed consent
- Patients who have received > 300 ml of albumin within 24 hours prior to inclusion
- Patients known to have previous adverse reaction to human albumin solution
- Patients who have religious restriction to receive human blood products
- Patient who have initial graft failure
- Patients with fluctuating hemodynamics
- Concerns of the treating surgeon
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Saline
|
100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
|
|
Experimental: 25% albumin
|
100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cardiac index (CI)
Time Frame: 60 minutes after the infusion of the fluid
|
60 minutes after the infusion of the fluid
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac function response
Time Frame: 30 and 60 minutes after the infusion of the fluid
|
An improvement in Q due primarily to a change in cardiac function should have an increase in Q of ≥ 0.3 ml/min/m2/mmHg
|
30 and 60 minutes after the infusion of the fluid
|
|
A decrease in leak and plasma expansion
Time Frame: 30 and 60 minutes after the infusion of the fluid
|
A decrease in leak and plasma expansion will be determined by the Harrison formula for calculating a change in plasma volume from the change in Hb and change in Hct
|
30 and 60 minutes after the infusion of the fluid
|
|
Cardiac output response
Time Frame: 30 and 60 minutes after the infusion of the fluid
|
Cardiac output response primarily due to a "volume effect" would be expected to have an increase of CVP of a minimum of 2 mmHg and an increase in CI of > 0.3 L/min/m2 per mmHg.
|
30 and 60 minutes after the infusion of the fluid
|
|
Detoxification effect of albumin
Time Frame: 30 and 60 minutes after infusion
|
A increase in vascular tone will be identified by an increase in systemic vascular resistance or a rise in blood pressure without a change in cardiac output or a rise in blood pressure with a fall in cardiac output
|
30 and 60 minutes after infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sheldon Magder, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 10-287-BMA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.